Surmodics to Webcast Fourth Quarter Fiscal 2020 Earnings Conference Call on November 4
Surmodics, Inc. (Nasdaq: SRDX) will host a live webcast on November 4, 2020, at 4 p.m. CT to discuss its fourth quarter fiscal 2020 results. The earnings release will be issued post-market close that day. CEO Gary Maharaj and CFO Tim Arens will detail financial results and accomplishments during the call. An audio replay will be available from 7 p.m. CT on November 4 until 7 p.m. CT on November 11. Surmodics specializes in surface modification technologies for medical devices and chemical components for in vitro diagnostic tests.
- None.
- None.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2020 conference call on Wednesday, November 4, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will recap the fourth quarter fiscal 2020 financial results and accomplishments. To access the webcast, go to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com the day of the conference call and click on the webcast icon.
An audio replay will be available beginning at 7 p.m. CT on Wednesday, November 4, until 7 p.m. CT on Wednesday, November 11, and can be accessed by dialing 888-203-1112 and entering conference call ID passcode 4873909. In addition, the conference call audio and transcript will be archived on the Company’s website following the call.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.